export const aboutTranslations = {
  en: {
    // Hero Section
    'hero.title': 'About Aurora2222',
    'hero.subtitle': 'A leading specialty pharmaceutical company dedicated to improving patient access to innovative therapeutic solutions across West Balkans and beyond',

    // Company Overview Section
    'overview.title': 'Our Company',
    'overview.description1': 'Since our establishment in 2013, Aurora2222 has been at the forefront of specialty pharmaceutical distribution, focusing on providing innovative therapeutic solutions and ensuring patient access to critical medications.',
    'overview.description2': 'Our commitment to excellence and patient care has made us a trusted partner in the healthcare industry, serving healthcare providers and patients across West Balkans',
    'overview.location.belgrade': 'Based in Belgrade',
    'overview.location.established': 'Established in 2013',

    // Mission & Vision Section
    'mission.title': 'Our Mission',
    'mission.description': 'To bridge critical gaps in healthcare accessibility by providing innovative therapeutic solutions and ensuring that patients receive the treatments they need, when they need them.',
    'vision.title': 'Our Vision',
    'vision.description': 'To be the leading facilitator of access to specialty medicines globally, known for our commitment to excellence, integrity, and patient-centered approach.',

    // Core Values Section
    'values.title': 'Our Core Values',
    'values.excellence.title': 'Excellence',
    'values.excellence.description': 'We strive for excellence in everything we do, from regulatory compliance to customer service.',
    'values.innovation.title': 'Innovation',
    'values.innovation.description': 'We embrace innovative solutions to complex healthcare challenges, staying ahead of industry developments.',
    'values.integrity.title': 'Integrity',
    'values.integrity.description': 'We maintain the highest ethical standards in all our operations and relationships.',

    // Journey Section
    'journey.title': 'Our Journey',

    // Timeline Events
    'timeline.2013.title': 'Foundation of Company',
    'timeline.2013.description': 'Company was founded in July 2013.',

    'timeline.2014.title': 'Obtained a WDL',
    'timeline.2014.description': 'The company was issued a wholesale dealers license by competent Authority - Ministry of Health. Guidelines for good practice in the distribution of human medicines have been adopted pursuant to Article 84 and Article 85 (b) (3) of Directive 2001/83 / EC and brought by Serbian MoH and published in "R Serbia Official Gazette" in 2016 but the Ministry is not issuing separate GDP certificate, by issuing WDL it is understood that wholesaler operates in accordance with GDP guidelines.',

    'timeline.2015.title': 'Establishment of strong portfolio',
    'timeline.2015.description': 'Through depth market analysis the company identified niche pharma products for placement on the market, with the focus on oncology and orphan drugs. Company completed registation in the register of bidders within the Serbian Bussines Registers Agency.',

    'timeline.2016.title': 'First supply and implementation of QMS',
    'timeline.2016.description': 'The company signed agreements with the most eminent health care centres in Belgrade and throughout Serbia. Started distribution to end users and also obtained and implemented ISO:9001 2008 QMS standard.',

    'timeline.2017.title': 'Porfolio and therapeutic area expansion',
    'timeline.2017.description': 'The company expanded therapeutic areas in which it is present to: haematology, cardiology, neurology, infectious diseases, anaesthesia, gastroenterology and psychiatry.',

    'timeline.2018.title': 'Extended reach in medicines supply',
    'timeline.2018.description': 'The company realised it\'s first supplies to the neighbouring markets. Completed implementation of ISO:9001 2015 QMS standard.',

    'timeline.2019.title': 'Introduction of new generic medicines',
    'timeline.2019.description': 'The company began distributing two new generic medications: one for brain/metastatic cancers and lymphomas (Hodgkins and non-Hodgkins), also used in hematopoietic progenitor cell transplantation; and another for rheumatoid arthritis.',

    'timeline.2020.title': 'Market access and exclusive distribution of an orphan drug',
    'timeline.2020.description': 'The company initiated the distribution of Dinituximab beta, an ultra-orphan drug indicated for the treatment of high-risk neuroblastoma (a rare childhood cancer). We provided the full spectrum of services required to facilitate fast-track market access, and withing six months, ensured that this innovative therapy became available to all children suffering from high-risk neuroblastoma in Serbia. We engaged in negotiations with the Republic Health Insurance Fund (RFZO) and secured reimbursement for all eligible patients in Serbia, while also obtaining exclusive distribution rights for the product. Furthermore, the company joined the wholesale distributors’ group within the Serbian Chamber of Commerce, thereby attaining full GIRP membership',

    'timeline.2021.title': 'Combatting COVID-19: Innovative therapeutic and diagnostic solutions',
    'timeline.2021.description': 'Amid the COVID-19 pandemic, the company provided therapeutic and diagnostic solutions, including therapies used in COVID-19 protocols and innovative self-test kits for rapid detection. The company also introduced a BCG vaccine brand for bladder tumor treatment and recurrence prophylaxis, addressing a critical therapy shortage.',

    'timeline.2022.title': 'Glutathione therapy and advancing neuroblastoma treatment',
    'timeline.2022.description': 'The company started distributing glutathione therapy to counter oxidative stress from chemotherapy and a therapy to reduce hemorrhagic cystitis caused by cyclophosphamide and ifosfamide. Also sponsored a Belgrade expert meeting on pediatric neuroblastoma treatment, featuring international experts and the latest research.',

    'timeline.2023.title': 'New exclusive distribution rights and exports to EU',
    'timeline.2023.description': 'The company secured exclusive distribution rights for two niche medicines in Serbia: for acute lymphoblastic leukemia (ALL) and a broad-spectrum antiviral (including anti-herpes and anti-HIV). Addressing an antivenom shortage, we partnered with the Torlak Institute to export VIEKVIN® to Germany, Austria, and Italy, integrating their full product portfolio and pursue further market expansion.',
    
    'timeline.2024.title': 'Market access and distribution of new orphan drugs',
    'timeline.2024.description': 'The company facilitated market access and initiated distribution of two novel breakthrough treatments in the fields of endocrinology and pediatric oncology, thereby strengthening its orphan drugs portfolio — palopegteriparatide, a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, and sodium thiosulfate injection, a therapy indicated to reduce the risk of cisplatin-induced ototoxicity in pediatric patients 1 month of age and older. Within a short time frame, the company successfully raised disease awareness and engaged in reimbursement negotiations with key stakeholders. Within three months, these efforts resulted in the initiation of treatment for the first patients in healthcare centers in Belgrade.',

    'timeline.2025.title': 'Registration and distribution of registered medicines',
    'timeline.2025.description': 'The company successfully finalized product registration of Trientine Waymade, a therapy indicated for the treatment of Wilson’s disease in patients who are intolerant to D-penicillamine, including adults, adolescents, and children aged 5 years and older, thus becoming the local MAH. Also company succesfuly registered an innovative nerve monitoring medical device, used during general anesthesia to monitor nerve and muscle activity, most commonly in thyroid and parathyroid surgery. Additionally, we began with distribution of the registered medicine Ponvory® (ponesimod), an innovative therapy for relapsing-remitting multiple sclerosis (RRMS). Palopegteriparatide and sodium thiosulfate therapies encompassed additional patients, with further treatment initiations taking place across several leading healthcare institutions throughout Serbia, supported by our continuous support in patient pathway coordination and activities that enhanced disease awareness. We continued the expansion and introduction of our niche unlicensed portfolio with several oncology products, including a new generic Thiotepa, a cytotoxic alkylating agent used in conditioning regimens prior to stem cell transplantation and in the treatment of select solid tumors, successfully initiating supply to key healthcare institutions.' 
  
  },
  sr: {
    // Hero Section
    'hero.title': 'O Aurora2222',
    'hero.subtitle': 'Vodeća specijalizovana farmaceutska kompanija posvećena poboljšanju pristupa pacijenata inovativnim terapeutskim rešenjima na Zapadnom Balkanu i šire.',

    // Company Overview Section
    'overview.title': 'Naša Kompanija',
    'overview.description1': 'Od osnivanja 2013. godine, Aurora2222 je u prvim redovima distribucije specijalnih farmaceutskih proizvoda, fokusirajući se na pružanje inovativnih terapeutskih rešenja i obezbeđivanje pristupa kritičnim lekovima.',
    'overview.description2': 'Naša posvećenost izvrsnosti i brizi o pacijentima učinila nas je pouzdanim partnerom u zdravstvenoj industriji, pružajući podršku zdravstvenim ustanovama i pacijentima širom Zapadnog Balkana.',
    'overview.location.belgrade': 'Sedište u Beogradu',
    'overview.location.established': 'Osnovano 2013. godine',

    // Mission & Vision Section
    'mission.title': 'Naša Misija',
    'mission.description': 'Premostiti kritične praznine u dostupnosti zdravstvene zaštite pružanjem inovativnih terapeutskih rešenja i osigurati da pacijenti dobiju potrebne tretmane kada su im potrebni.',
    'vision.title': 'Naša Vizija',
    'vision.description': 'Biti vodeći facilitator pristupa specijalnim lekovima na globalnom nivou, poznat po posvećenosti izvrsnosti, integritetu i pristupu usmerenom ka pacijentu.',

    // Core Values Section
    'values.title': 'Naše Osnovne Vrednosti',
    'values.excellence.title': 'Izvrsnost',
    'values.excellence.description': 'Težimo izvrsnosti u svemu što radimo, od regulatorne usklađenosti do korisničke usluge.',
    'values.innovation.title': 'Inovacija',
    'values.innovation.description': 'Prihvatamo inovativna rešenja za složene zdravstvene izazove, održavajući korak sa razvojem industrije.',
    'values.integrity.title': 'Integritet',
    'values.integrity.description': 'Održavamo najviše etičke standarde u svim našim operacijama i odnosima.',

    // Journey Section
    'journey.title': 'Naš Put',

    // Timeline Events
    'timeline.2013.title': 'Osnivanje Kompanije',
    'timeline.2013.description': 'Kompanija je osnovana u julu 2013. godine.',

    'timeline.2014.title': 'Dobijanje Veleprodajne Dozvole',
    'timeline.2014.description': 'Kompanija je dobila veleprodajnu dozvolu od nadležnog organa - Ministarstva zdravlja. Smernice za dobru praksu u distribuciji humanih lekova usvojene su u skladu sa članom 84 i članom 85 (b) (3) Direktive 2001/83/EC i donete od strane srpskog Ministarstva zdravlja i objavljene u "Službenom glasniku RS" 2016. godine, ali Ministarstvo ne izdaje poseban GDP sertifikat, izdavanjem veleprodajne dozvole podrazumeva se da veleprodaja posluje u skladu sa GDP smernicama.',

    'timeline.2015.title': 'Uspostavljanje jakog portfolija',
    'timeline.2015.description': 'Kroz detaljnu analizu tržišta kompanija je identifikovala niša farmaceutske proizvode za plasiranje na tržište, sa fokusom na onkologiju i lekove za retke bolesti. Kompanija je završila registraciju u registru ponuđača u okviru Agencije za privredne registre Srbije.',

    'timeline.2016.title': 'Prva isporuka i implementacija QMS-a',
    'timeline.2016.description': 'Kompanija je potpisala ugovore sa najeminentnijim zdravstvenim centrima u Beogradu i širom Srbije. Započela distribuciju krajnjim korisnicima i takođe dobila i implementirala ISO:9001 2008 QMS standard.',

    'timeline.2017.title': 'Proširenje portfolija i terapeutskih oblasti',
    'timeline.2017.description': 'Kompanija je proširila terapeutske oblasti u kojima je prisutna na: hematologiju, kardiologiju, neurologiju, infektivne bolesti, anesteziju, gastroenterologiju i psihijatriju.',

    'timeline.2018.title': 'Prošireni domet u snabdevanju lekovima',
    'timeline.2018.description': 'Kompanija je realizovala prve isporuke na susedna tržišta. Završena implementacija ISO:9001 2015 QMS standarda.',

    'timeline.2019.title': 'Uvođenje novih generičkih lekova',
    'timeline.2019.description': 'Lansirana su dva nova generička leka: jedan za tumore mozga/metastatske karcinome i limfome (Hodžkin i ne-Hodžkin), koji se takođe koristi u transplantaciji hematopoetskih progenitorskih ćelija; i drugi za reumatoidni artritis.',

    'timeline.2020.title': 'Pristup tržištu i ekskluzivna distribucija leka za lečenje retke bolesti',
    'timeline.2020.description': 'Kompanija je započela distribuciju leka Dinituximab beta, ultra-orphan terapije indikovane za lečenje visokorizičnog neuroblastoma (retkog dečijeg kancera). U roku od šest meseci, pružili smo kompletan spektar usluga neophodnih kako bi se obezbedio ubrzan pristup terapiji, čime je omogućeno da ovaj inovativni lek postane dostupan deci oboleloj od visokorizičnog neuroblastoma u Srbiji. Kompanija je sprovela sve potrebne korake kako bi se stvorili uslovi za uvođenje ove ciljane onkološke terapije na tržište Srbije i istovremeno obezbedili ekskuzivna prava distribucije. Vodili smo pregovore sa Republičkim fondom za zdravstveno osiguranje (RFZO), čime je obezbeđena refundacija terapije za sve kvalifikovane pacijente u Srbiji. Takođe, kompanija se pridružila grupaciji veledrogerija pri Privrednoj komori Srbije, čime je stekla puno GIRP članstvo',

    'timeline.2021.title': 'Borba protiv COVID-19: Inovativna terapeutska i dijagnostička rešenja',
    'timeline.2021.description': 'Tokom COVID-19 pandemije, kompanija je obezbedila terapeutska i dijagnostička rešenja, uključujući terapije korišćene u COVID-19 protokolima i inovativne self-test kitove za brzu detekciju. Takođe su uveli BCG vakcinu za lečenje tumora bešike i profilaksu recidiva, rešavajući kritičnu nestašicu terapije.',

    'timeline.2022.title': 'Glutationska terapija i unapređenje lečenja neuroblastoma',
    'timeline.2022.description': 'Započeli smo distribuciju glutationske terapije indikovane za suzbijanje oksidativnog stresa od hemoterapije i terapije za smanjenje hemoragičnog cistitisa uzrokovanog ciklofosfamidom i ifosfamidom. Takođe smo sponzorisali stručni sastanak u Beogradu posvećen lečenju pedijatrijskog neuroblastoma, uz učešće međunarodnih i domaćih stručnjaka, gde su predstavljena najnovija istraživanja',

    'timeline.2023.title': 'Nova ekskluzivna distributivna prava i izvoz u EU',
    'timeline.2023.description': 'Obezbedili smo ekskluzivna distributivna prava za dva nišna leka u Srbiji: za akutnu limfoblastnu leukemiju (ALL) i širokospektralni antivirusni lek (uključujući anti-herpes i anti-HIV). Identifikovana je nestašica antiseruma protiv zmijskog otrova u EU, i uspostavljeno je partnerstvo sa Institutom Torlak radi izvoza leka VIEKVIN® u Nemačku, Austriju i Italiju.  Partnerstvo je obuhvatilo i celokupni Torlakov portfolio, radi potencijalnog plasmana na nova tržišta.',

    'timeline.2024.title': 'Pristup tržištu i distribucija novih lekova za lečenje retkih bolesti',
    'timeline.2024.description': 'Kompanija je omogućila pristup tržištu i započela distribuciju dva nova, revolucionarna terapijska rešenja iz oblasti endokrinologije i pedijatrijske onkologije, čime je dodatno ojačala svoj portfolio lekova za lečenje retkih bolesti — palopegteriparatid, terapija zasnovana na paratireoidnom hormonu (PTH) namenjena lečenju odraslih pacijenata sa hroničnim hipoparatiroidizmom, i natrijum-tiosulfat injekcija, terapija indikovana za smanjenje rizika od ototoksičnosti izazvane cisplatinom kod pedijatrijskih pacijenata starosti od jednog meseca naviše. U kratkom vremenskom periodu, kompanija je uspešno podigla svest o ovim oboljenjima i otpočela pregovore o refundaciji sa ključnim stejkholderima. Nakon 3 meseca, ovi napori doveli su do započinjanja lečenja prvih pacijenata u zdravstvenim ustanovama u Beogradu.',

    'timeline.2025.title': 'Registracija i distribucija registrovanih proizvoda',
    'timeline.2025.description': 'Kompanija je uspešno finalizovala registraciju leka Trientine Waymade, terapije indikovane za lečenje Vilsonove bolesti kod pacijenata koji ne podnose D-penicilamin, uključujući odrasle, adolescente i decu uzrasta od 5 godina i starije, čime je postala lokalni nosilac dozvole za ovaj lek (MAH). Pored toga, započeta je distribucija registrovanog leka Ponvory® (ponesimod), inovativne terapije za relapsno-remitirajuću multiplu sklerozu (RRMS). Terapije palopegteriparatidom i natrijum-tiosulfatom obuhvatile su dodatne pacijente, a lečenje je prošireno na više vodećih zdravstvenih ustanova širom Srbije, uz kontinuiranu podršku naše kompanije pri organizaciji pristupa terapiji i aktivnostima koje su doprinele unapređenju svesti o oboljenjima.'
  }
};